|
KMID : 0191120150300020173
|
|
Journal of Korean Medical Science
2015 Volume.30 No. 2 p.173 ~ p.179
|
|
|
The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
|
|
Byun Ja-Min
Lee Chang-Kyun
Rhee Sang-Youl
Kim Hyo-Jong
Kim Jung-Wook
Shim Jae-Jun
Jang Jae-Young
|
|
|
Abstract
|
|
|
|
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor (TNF)-α blockers. We reviewed medical records of 525 Korean IBD patients (365 TNF-α blocker naive and 160 TNF-α blocker exposed) between January 2001 and December 2013. The crude incidence of TB was significantly higher in IBD patients receiving TNF-α blockers compared to TNF-α-blocker-naive patients (3.1% vs. 0.3%, P=0.011). The mean incidence of TB per 1,000 patient-years was 1.84 for the overall IBD population, 4.89 for TNF-α blocker users, and 0.45 for TNF-α-blocker-naive patients. The adjusted risk ratio of TB in IBD patients receiving TNF-α blocker was 11.7 (95% confidence interval, 1.36-101.3). Pulmonary TB was prevalent in patients treated with TNF-α blockers (80.0%, 4/5). LTBI was diagnosed in 17 (10.6%) patients, and none of the 17 LTBI patients experienced reactivation of TB during treatment with TNF-α blockers. Treatment with TNF-α blockers significantly increased the risk of TB in IBD patients in Korea. De novo pulmonary TB infection was more prevalent than reactivation of LTBI, suggesting an urgent need for specific recommendations regarding TB monitoring during TNF-α blocker therapy.
|
|
|
KEYWORD
|
|
|
Tuberculosis, Latent Tuberculosis, Tumor Necrosis Factor-alpha, Inflammatory Bowel Disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|